Overview

Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the absorption of a niacin metabolite (1-methylnicotinamide, 1-MNA) from TRIA-662 (1-methylnicotinamide chloride)relative to the production of 1-MNA from Niaspan. The 1-MNA information obtained from this study will be used to adjust the top dose of a planned TRIA-622 efficacy study.
Phase:
Phase 1
Details
Lead Sponsor:
Cortria Corporation
Collaborators:
Pharmena North America
PPD
Treatments:
Niacin
Nicotinic Acids